The global HLA typing for transplant market size stood at USD 1.11 billion in 2025, grew to USD 1.18 billion in 2026, and is forecast to reach USD 1.97 billion by 2035, expanding at a CAGR of 5.93% from 2026 to
The HLA typing for transplant market is experiencing robust growth, driven by the increasing organ transplantation procedures and the rising prevalence of chronic disorders. The growing public-private partnerships and increasing investments boost the market. Numerous government organizations support organ transplantations by launching initiatives. Integrating artificial intelligence (AI) in HLA typing aids in data analysis and interpretation, thereby enhancing efficiency and accuracy. The future looks promising, with advancements in genomic technologies.
HLA (Human Leukocyte Antigen) typing for transplant is a molecular diagnostic process that identifies genetic compatibility between donors and recipients by determining the specific variants of HLA genes. These antigens, located on the surface of white blood cells, play a vital role in immune response regulation. Accurate HLA matching minimizes the risk of organ rejection and graft-versus-host disease (GVHD), making it a critical step in solid organ transplantation and hematopoietic stem cell transplantation (HSCT). The HLA typing market encompasses various technologies and services used in clinical labs, hospitals, transplant centers, and research settings to perform genotyping and antigen detection.
AI plays a vital role in performing numerous functions, such as identifying interactions of HLA antibodies, HLA genotype, and donor HLA expression. AI and machine learning (ML) algorithms can analyze vast amounts of data and determine patterns in HLA data. They can also identify potential HLA-associated diseases in a patient. AI and ML can simplify the interpretation of HLA analysis data, reducing manual errors. AI aids researchers in developing personalized medicines based on the results of HLA typing and the HLA alleles involved.
Driver
Demand for Organ Transplants
The major growth factor for the HLA typing for transplant market is the growing demand for organ transplantations. This is due to the rising prevalence of chronic disorders, such as cardiovascular disorders, chronic kidney disease, and hepatic disorders. The prolonged condition of such disorders leads to organ failure, potentiating the demand for organ transplants. The WHO reported that more than 150,000 solid organ transplants are performed globally each year. Government organizations raise awareness among the general public about organ donations.
Restraint
Lack of Skilled Professionals
Certain underdeveloped and developing countries have a lack of skilled professionals to understand the clinical significance of different alleles. The HLA typing system is complex and polymorphic, requiring specialized expertise.
Opportunity
What is the Future of the HLA Typing for Transplant Market?
The market future is promising, driven by advancements in genomic technologies. Next-generation sequencing (NGS) offers effective solutions for complex HLA typing. The use of bioinformatics mitigates the risk of sequencing errors. Researchers are developing online software tools for sequencing. Advances in genomic technologies enhance the efficiency and reproducibility of sequencing techniques, expanding their services. This leads to lower costs and swift turnaround times, accelerating the speed of overall diagnosis. Technological advancements present ample opportunities for market players and improve diagnostic precision.
| Metric | Details |
| Market Size in 2026 | USD 1.18 Billion |
| Projected Market Size in 2035 | USD 1.97 Billion |
| CAGR (2026 - 2035) | 5.93% |
| Leading Region | North America Share 38% |
| Historical Data | 2020 - 2023 |
| Base Year | 2025 |
| Forecast Period | 2026 - 2035 |
| Measurable Values | USD Millions/Units/Volume |
| Market Segmentation | By Products & Services, By Technology, By Application, By End-User, By Region |
| Top Key Players | Thermo Fisher Scientific, Bio-Rad Laboratories, QIAGEN N.V., F. Hoffmann-La Roche Ltd, Immucor Inc., CareDx, Inc., Illumina, Inc., Omixon Inc., GenDx, HistoGenetics, Becton, Dickinson and Company, Bio-Techne Corporation, Luminex Corporation (Now part of DiaSorin), Takara Bio Inc., Abbott Molecular, TBG Diagnostics, BAG Health Care GmbH, Linkage Biosciences (acquired by Thermo Fisher), Labcorp, Eurofins Scientific |
By product & services, the reagents & consumables segment held a dominant presence in the market by 50% share in 2025. This is due to the easy availability of reagents and their affordability. Reagents & consumables enable researchers to perform multiple experiments simultaneously. Key players offer a wide range of reagents, such as PCR and flow cytometry reagents and sequencing kits, for research and clinical purposes. Researchers can refill their research requirements through reagents.
By product & services, the software & services segment is expected to grow at the fastest CAGR in the market during the forecast period. Software & services eliminate the need for specialized infrastructure. They also reduce the cost of regular maintenance of instruments. Services provide relevant expertise to complex research problems. Ongoing efforts are made to develop advanced software to simplify data analysis and interpretation.
By technology, the molecular assay technologies segment held the largest revenue share of 35% of the market in 2025 and is expected to expand rapidly in the market in the coming years. This segment dominated because of the burgeoning molecular biology sector and advances in assay techniques. Molecular assay technologies enable the measurement of molecular characteristics and interactions. Researchers develop advanced instruments to enhance the precision of assay methodologies and aid in data analysis. Molecular assay technologies provide a deeper understanding of HLA variants and the compatibility of transplants.
The PCR-based molecular typing sub-segment dominated the market. Polymerase chain reaction (PCR) is a conventional gene sequencing technique to amplify specific DNA sequences. This technique is widely preferred due to its accuracy, reliability, high speed, and sensitivity. It is cost-effective and can analyze small amounts of DNA samples.
The NGS-based sequencing sub-segment is expected to grow rapidly. Next-generation sequencing (NGS) is a more advanced gene sequencing technique with higher sensitivity, precision, and accuracy compared to the PCR technique. It can detect rare genetic variants and screen multiple samples cost-effectively.
By application, the solid organ transplantation segment contributed the biggest revenue share of 45% of the market in 2025. This is due to the rising prevalence of chronic disorders, leading to organ failures. HLA typing is essential to assess the compatibility of the donor organ with the recipient. Several government organizations encourage people to donate organs. The increasing number of organ transplantations globally potentiates the need for HLA typing.
The kidney sub-segment held a major revenue share. The rising prevalence of chronic kidney disorder (CKD) and the increasing number of kidney transplants propel the segment’s growth. It is estimated that over 700 million people in the world have CKD. Kidney transplants were the highest among all organ transplants in the U.S., accounting for 27,759 in 2024, an increase of 1.6%.
By application, the stem cell transplantation segment is expected to witness the fastest growth in the market over the forecast period. The growing demand for personalized medicines and expanding applications of stem cells augment the segment’s growth. Allogeneic stem cell transplantation is a procedure that requires HLA typing, as stem cells from different individuals are transferred to the patient. The donor may or may not be related to the recipient. It is preferred for different blood cancers, such as leukemia, myelofibrosis, and lymphoma.
By end-user, the hospitals & transplant centers segment led the global market by 40% share in 2025. Hospitals & transplant centers have favorable infrastructure and suitable capital investment to adopt advanced technologies. They have skilled professionals to perform HLA typing tests and consult patients. The increasing number of organ transplants also contributes to the segment’s growth.
By end-user, the biopharmaceutical companies segment is expected to show the fastest growth in the upcoming years. HLA typing is essential for research purposes, including drug development, personalized medicine, and transplantation. Biopharmaceutical companies have advanced research infrastructure and trained professionals. The growing number of biopharma startups increases competition among key players. This enables them to develop and launch innovative HLA typing products.
North America dominated the global market share by 38% in 2025. The presence of a robust healthcare infrastructure, the increasing number of organ transplantations, and favorable government support are factors that govern the market growth in North America. The rising investments and collaborations among key players favor market growth. The presence of key players contributes to market growth by providing advanced HLA typing test tools.
U.S. Market Trends
The Organ Procurement and Transplantation Network (OPTN) reported that 48,149 organ transplants were performed in the U.S. in 2024, representing an increase of 3.3% from 2023. Key players, such as Illumina, Inc., Bio-Techne Corporation, and Labcorp, are the major contributors to the market in the U.S.
Canada Market Trends
In 2024, a total of 3,212 organ transplants were performed in Canada, of which 82% organ donations were from deceased donors and 18% used living donors’ organs. The Government of Canada announced an investment of $2 million to focus on cutting-edge research in the area of organ and tissue donation. The funding was made to help institutions develop and test their AI prototype to match organ donors with recipients.
Asia-Pacific is expected to grow at the fastest CAGR in the HLA typing for transplant market during the forecast period. The increasing awareness of organ donations and favorable government initiatives bolster market growth. Government organizations organize campaigns and create social media awareness to promote organ donations. The rising prevalence of chronic disorders and the growing geriatric population potentiates the demand for HLA typing.
China Market Trends
Chinese Premier signed a decree of the State Council to unveil rules on human organ donation and transplantation to meet the demands of changing procedures and ensure the healthy development of the cause. As of 2024, more than 7 million people were registered as organ donors. China recorded more than 58,000 organ donations, 63,000 body donations, and 110,000 corneal donations.
India Market Trends
In 2024, India performed over 18,900 organ transplants, setting a new record for the highest number in a single year. It ranks third globally in organ transplants, after the U.S. and China. The Indian government has also launched a national campaign, “Angdaan-Jeevan Sanjeevani Abhiyan”, to promote organ and tissue donation across the country.
Europe is expected to grow at a notable CAGR in the HLA typing for transplant market in the foreseeable future. The rising adoption of advanced technologies and increasing investments boost the market. The growing public-private partnerships and suitable government support propel market growth. The increasing awareness about HLA typing’s significance in successful transplants and the growing demand for personalized medicines facilitate market growth. The expansion of donor registries in European countries provides organs to patients.
UK Market Trends
The NHS Blood and Transplant (NHSBT) estimates that only around 100,000 donors are HLA typed. Hence, it launched a pilot programme to help reduce the formation of immune system antibodies and transplant rejection. NHSBT predicts that at least 130,000 blood donors will need to be HLA typed to make the full supply of HLA-matched red cells for kidney transplant patients
Germany Market Trends
Germany manages low donation volumes through precise molecular testing within the HLA typing for transplant market. In 2024, the nation recorded 953 post-mortem donors and performed 3,013 transplants. Despite these low numbers compared to EU peers, over 8,200 individuals remain on active waiting lists. To optimize matching outcomes, laboratories rely heavily on high-resolution NGS technologies. Pending legislation changes targeting national kidney exchange structures will heavily impact diagnostic workflows and lab testing requirements.
A unified emphasis on immunological compatibility shapes the HLA typing for transplant market in Latin America. Regional health ministries actively fund the modernization of reference laboratories to expand molecular diagnostic accessibility. This continuous infrastructure investment directly supports broader bone marrow and solid organ registries. Clinical teams work closely to reduce post-transplant rejection episodes through standardized screening protocols. Consequently, smaller nations leverage shared genetic databases to match highly sensitized patients safely across borders.
Brazil Market Trends
Government-backed programs strongly elevate the HLA typing for transplant market in Brazil. The country represents a dominant force in South American transplantation, successfully executing 26,509 total transplants in 2024. This immense volume includes 6,297 kidney and 2,449 liver procedures. To maintain excellent clinical outcomes for a vast patient population, state laboratories prioritize advanced molecular typing. Expanded healthcare access across the growing middle class guarantees consistent demand for matching kits.
Argentina Market Trends
In Argentina, the HLA typing for transplant market expands alongside rising national donation rates. The country achieved 2,232 solid organ transplants in 2024, driven by 803 deceased donors. National university labs provide top-tier scientific talent to run complex serological and genetic matching procedures. Local medical teams excel at coordinating long-distance sample logistics to hit critical transplant windows. International research partnerships help Argentine clinics update their typing technologies to meet strict global compatibility rules.
State-driven healthcare visions fund advanced diagnostic networks. The HLA typing for transplant market in MEA experiences notable development as governments invest heavily in building domestic clinical infrastructure. New diagnostic facilities are emerging to screen larger patient cohorts locally rather than outsourcing samples abroad. However, logistics networks face challenges delivering viable cellular samples from rural areas to centralized cities. Despite these hurdles, national health initiatives are successfully building extensive regional donor databases to support growing bone marrow transplant programs.
UAE Market Trends
Innovative digital tools transform the HLA typing for transplant market in the UAE. The country accelerates matching workflows by integrating automated data tracking into high-tech urban laboratories. Local health authorities offer highly competitive incentives to attract global biotechnology vendors and specialist immunologists. These modern diagnostic setups ensure rapid, high-resolution typing for a diverse, multinational patient base. Expanding specialized medical hubs allows the nation to position itself as a key regional center for complex living-donor procedures.
Saudi Arabia Market Trends
The HLA typing for transplant market in Saudi Arabia is accelerating due to Vision 2030 modernization programs. The nation boasts exceptionally high living donation rates, exceeding 50 donors per million people. In 2024 alone, living donors provided 1,284 kidneys and 422 liver segments. Over 540,000 citizens are registered on national donor applications to streamline the allocation process. Highly accredited specialized transplant centers rely heavily on precise molecular screening to manage these rapidly expanding clinical volumes safely.
Prof. Samaila Mungadi, the Director of the UDUTH Center, Sokoto, at the Transplant inaugural program, commented on the successful completion of the kidney transplant that extensive tests were performed to assess kidney function, overall health, and compatibility for the transplant. Different tests include blood tests, imaging, and tissue matching (HLA typing).
By Products & Services
By Technology
By Application
By End-User
By Region
Principal Consultant
Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.
Learn more about Payal Rabde
Reviewed By
Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.
Learn more about Aditi Shivarkar
